Back to Awarded Treatment Trials


Awarded Trial: 00-091

Grant ID

00-091

Illness

Bipolar Disorder with Comorbid Alcohol Abuse/Dependence

Primary Drug/Intervention

Olanzapine

Primary Dosage

Flexible Dosing

Secondary Drug Intervention

Divalproex

Secondary Dosage

Flexible Dosing

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Frye

Sample Size

50

Duration of Study Period for Each Subject

52 weeks

Outcome Measurements

Return to hazardous drinking

Results

Only 3 subjects were able to complete the entire study but Cox proportional hazard regression allowed for data analysis. For most subjects there was no significant advantage for either drug. For a small group of bipolar women, there was a possible benefit for divalproex. The small sample and study design prevent a conclusive interpretation of these data.

Publication

N/A

Link

N/A

PI Name

Mark Frye

Degree

MD

Center

N/A

Institution

UCLA

Address

300 UCLA Medical Plaza, Suite 1544

City or Town

Los Angeles

State or Province

CA

Zip or Postal Code

90095

Country

USA

Email Address

mfrye@mednet.ucla.edu